Novavax

Novavax

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

Novovax is a clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology. The company’s vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins that are critical to disease pathogenesis.

Novovirus generates their vaccine nanoparticles in insect cells. Cells of the fall armyworm, Spodoptera frugiperda, are grown as a cell line called Sf9. When infected with baculovirus, they have can continue to multiply indefinitely. The baculovirus is engineered to carry foreign genes to program the Sf9 cells to produce desired proteins. Recombinant proteins are designed to self-assemble into nanoparticle constructs in such a way as to elicit a strong immune response.

Novavax’s lead product is a nanoparticle flu vaccine called NanoFlu. The company developed vaccines for SARS and Middle East respiratory syndrome, that have not received regulatory approval. Novavax developed a RSV (respiratory syncytial virus) vaccine called ResVax that failed in two late-stage clinical studies. Novavax is working on a vaccine for the new coronavirus responsible for the COVID-19 outbreak.

Timeline

January 28, 2021
An experimental coronavirus vaccine developed by Novavax is 89.3 percent effective at preventing Covid-19.

Moderna announced this week that its vaccine appears to be less effective against the South African variant, although it said protective antibodies remained above protective levels.

November 9, 2020
Novavax appoints Gregory F. Covino as Chief Financial Officer.
July 7, 2020
Novavax raises a $1,600,000,000 grant.
June 15, 2020
Novavax raises a $200,000,000 private equity from RA Capital Management.
May 26, 2020
Novavax announces it received $384 million from CEPI.
May 11, 2020
Novavax raises a $384,000,000 grant from Coalition for Epidemic Preparedness Innovations.
March 10, 2020
Novavax raises a $4,000,000 grant from Coalition for Epidemic Preparedness Innovations.
2020
Novavax announces starting human trials of a vaccine and expects to release a tested vaccine by this year.
September 29, 2015
Novavax raises a $89,000,000 grant from Bill & Melinda Gates Foundation.
September 13, 2013
Novavax raises a $94,600,000 private equity.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Novavax Grant (money), September 2015
89,000,000
September 29, 2015
7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Gregory Glenn, MD

President of Research and Development

Further reading

Title
Author
Link
Type
Date

COVID-19 Vaccine Development Update: An Interview With Novavax

Molly Campbell

Web

March 26, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
March 2, 2021
FierceBiotech
Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The goal suggests the U.S. could join the U.K. on the list of countries to authorize the vaccine in the first half of the year.
Grace Dean
March 2, 2021
Business Insider
Novavax's CEO, Stanley Erck, said its COVID-19 vaccine could be authorized in the UK first before the FDA gives it emergency use authorization (EUA).
Sohini Das
February 19, 2021
@bsindia
Novavax has signed a memorandum of understanding (MoU) in this regard with Gavi, the Vaccine Alliance.
Isabelle Lee
February 19, 2021
markets.businessinsider.com
Novavax is working with GAVI to promote equal access to its COVID-19 vaccine globally. The company will supply 1.1 billion doses under the agreement.
Telegraph reporters
February 7, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Telegraph reporters
February 7, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Telegraph reporters
February 6, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Sohini Das
February 5, 2021
@bsindia
As for Bharat Biotechs chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials
Sohini Das
February 5, 2021
@bsindia
As for Bharat Biotechs chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials
Amirah Al Idrus
February 5, 2021
FierceBiotech
On the heels of COVID-19 pacts with Bayer and GlaxoSmithKline, CureVac is joining forces with the U.K. government to tackle the next challenge--new variants of the SARS-CoV-2 virus. If approved, any vaccines that come out of the deal will be distributed in the U.K. and its overseas and dependent territories.
Telegraph reporters
February 5, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Telegraph reporters
February 4, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Financialnewsmedia.com
February 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Advances in technology and decreasing costs have led to an increased use of unmanned aerial vehicles (UAVs) by the military and civilian...
Megan Molteni
February 3, 2021
Wired
As emerging mutations threaten the progress made against the pandemic, scientists and regulators are racing to figure out a process for updating shots.
Telegraph reporters
February 3, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Telegraph reporters
February 2, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Graham Lawton, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
February 1, 2021
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Telegraph reporters
February 1, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
Telegraph reporters
January 31, 2021
The Telegraph
The Covid-19 vaccination programme is under way - the largest in British history
ANI
January 30, 2021
@bsindia
SII is already manufacturing millions of doses of Covishield vaccine in technical collaboration with Oxford University and AstraZeneca
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.